BROOMFIELD, CO, June 14, 2024 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environmental, renewable fuels and industrial waste stream management services, recently had its wholly-owned operating company, SEM, LLC, receive a new purchase order to provide kilns to Biochar Now, LLC ("BCN") (www.biocharnow.com). The purchase order totals approximately $600,000 and is part of BCN's nationwide expansion program. It was recently announced that BCN, in col ...

Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation Omid Farokhzad, M.D., Chair & Chief Executive Officer of Seer said, "Exploring the effects of space flight on the human body presents an intriguing frontier for proteomic research. These papers highlight Seer's technology to provide unbiased insights into the proteome and shed light on dysfunctional biological alterations. At Seer, we empower researchers in detecting proteins and pept ...

Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation Omid Farokhzad, M.D., Chair & Chief Executive Officer of Seer said, "Exploring the effects of space flight on the human body presents an intriguing frontier for proteomic research. These papers highlight Seer's technology to provide unbiased insights into the proteome and shed light on dysfunctional biological alterations. At Seer, we empower researchers in detecting proteins and pept ...

REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma biomarker study to date utilizing the Seer Proteograph™ Product Suite and Thermo Fisher Scientific's Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer. This pioneering research involved a multi-cancer case-control cohort of 2,840 su ...

Seer, Inc. (NASDAQ:SEER) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Omid Farokhzad - Chief Executive Officer & Chair David Horn - President & Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Seer, Inc. First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there wi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-39747 SEER, INC. (Exact name of Registrant as specified in its charter) Delaware 82-1153150 ...

Seer Reports First Quarter 2024 Financial Results Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications REDWOOD CITY, Calif. May 8, 2024 – Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Achieved revenue of $3.1 million for the first quarter of 2024 • Announced the expansion of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 3800 Bridge Parkway, ...

Company Participants Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Marta Nazarovets - JPMorgan Chase And now, I'd like to introduce your host for today's program, Carrie Mendivil, Investor Relations. Before we begin, I'd like to remind you that management will make statements during this call that are forwardlooking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from tho ...

Exhibit 99.1 Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data REDWOOD CITY, Calif. February 29, 2024 – Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights "In 2023, our customers cont ...